Literature DB >> 33077615

Leveraging the Capabilities of the FDA's Sentinel System To Improve Kidney Care.

Sruthi Adimadhyam1, Erin F Barreto2,3, Noelle M Cocoros4, Sengwee Toh4, Jeffrey S Brown4, Judith C Maro4, Jacqueline Corrigan-Curay5, Gerald J Dal Pan5, Robert Ball5, David Martin5, Michael Nguyen5, Richard Platt4, Xiaojuan Li4.   

Abstract

The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program's experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  Sentinel Initiative; U.S. Food and Drug Administration; electronic health data; epidemiology; outcomes research; real-world evidence

Mesh:

Year:  2020        PMID: 33077615      PMCID: PMC7608970          DOI: 10.1681/ASN.2020040526

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  43 in total

1.  The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.

Authors:  Michael Nguyen; Robert Ball; Karen Midthun; Tracy A Lieu
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

2.  Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care.

Authors:  Jeffrey S Brown; John H Holmes; Kiran Shah; Ken Hall; Ross Lazarus; Richard Platt
Journal:  Med Care       Date:  2010-06       Impact factor: 2.983

Review 3.  Pharmacology behind Common Drug Nephrotoxicities.

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2018-04-05       Impact factor: 8.237

4.  Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk.

Authors:  James H Flory; Jason Roy; Joshua J Gagne; Kevin Haynes; Lisa Herrinton; Christine Lu; Elisabetta Patorno; Azadeh Shoaibi; Marsha A Raebel
Journal:  J Comp Eff Res       Date:  2016-12-09       Impact factor: 1.744

5.  The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Harish Seethapathy; Sophia Zhao; Donald F Chute; Leyre Zubiri; Yaa Oppong; Ian Strohbehn; Frank B Cortazar; David E Leaf; Meghan J Mooradian; Alexandra-Chloé Villani; Ryan J Sullivan; Kerry Reynolds; Meghan E Sise
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-31       Impact factor: 8.237

Review 6.  Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.

Authors:  Anawin Sanguankeo; Sikarin Upala; Wisit Cheungpasitporn; Patompong Ungprasert; Eric L Knight
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

7.  Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study.

Authors:  Khaled Abdel-Kader; Raquel C Greer; L Ebony Boulware; Mark L Unruh
Journal:  BMC Nephrol       Date:  2014-04-22       Impact factor: 2.388

Review 8.  Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

Authors:  Brendon L Neuen; Meg J Jardine; Vlado Perkovic
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

9.  Comparison of privacy-protecting analytic and data-sharing methods: A simulation study.

Authors:  Kazuki Yoshida; Susan Gruber; Bruce H Fireman; Sengwee Toh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-07-18       Impact factor: 2.890

10.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
View more
  3 in total

Review 1.  Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations.

Authors:  Jenna Wong; Daniel Prieto-Alhambra; Peter R Rijnbeek; Rishi J Desai; Jenna M Reps; Sengwee Toh
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

Review 2.  Big Data in Nephrology.

Authors:  Navchetan Kaur; Sanchita Bhattacharya; Atul J Butte
Journal:  Nat Rev Nephrol       Date:  2021-06-30       Impact factor: 28.314

3.  Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study.

Authors:  Yanglin Hu; Li Xu; XiaoHui Wang; Xiaofei Qin; Sheng Wan; Qing Luo; Yanqiong Ding; Xiaofen Xiao; Fei Xiong
Journal:  Int Urol Nephrol       Date:  2021-06-19       Impact factor: 2.370

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.